Adriana Ribeiro

Dr. Adriana Ribeiro

Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Dept. of Pharmacy, Pharmacology and Health Technologies, Universidade de Lisboa., Lisbon, Lisboa, Portugal
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2025 in Molecules
Verified
Journal Article
Open access
PDF file
Adriana RibeiroAdriana Ribeiro
Adriana Ribeiro
DODaniele Oliveira
Daniele Oliveira
HCHelena Cabral-Marques
Helena Cabral-Marques
Ocular diseases affecting the anterior and posterior segments of the eye are major causes of global vision impairment. Curcumin, a natural polyphenol, exhibits anti-inflammatory, antioxidant, antibacterial, and neuroprotective properties, making it a promising candidate for ocular therapy. However, its clinical use is hindered by low aqueous solubility, poor bioavailability, and rapid systemic elimination. This review comprehensively highlights advances in curcumin delivery systems aimed at overcoming these challenges. Emerging platforms, including proniosomal gels, transferosomes, and cyclodextrin complexes, have improved solubility, permeability, and ocular retention. Nanoparticle-based carriers, such as hybrid hydrogels and biodegradable nanoparticles, enable sustained release and targeted delivery, supporting treatments for posterior segment diseases like diabetic retinopathy and age-related macular degeneration. For anterior segment conditions, including keratitis and dry eye syndrome, cyclodextrin-based complexes and mucoadhesive systems enhance corneal permeability and drug retention. Mechanistically, curcumin modulates key pathways, such as NF-κB and TLR4, reducing oxidative stress, angiogenesis, and apoptosis. Emerging strategies like photodynamic therapy and neuroprotective approaches broaden their application to eyelid conditions and neuroinflammatory ocular diseases. These advancements address curcumin’s pharmacokinetic limitations, supporting its clinical translation into ophthalmic therapies. This work underscores curcumin’s potential in ocular disease management and advocates clinical trials to validate its safety, efficacy, and therapeutic relevance.

31 July 2023 in Plants
Verified
Journal Article
Open access
PDF file
Adriana RibeiroAdriana Ribeiro
Adriana Ribeiro
RSRita Serrano
Rita Serrano
ISIsabel Bettencourt Moreira da Silva
Isabel Bettencourt Moreira da Silva
EGElsa T. Gomes
Elsa T. Gomes
JPJoão F. Pinto
João F. Pinto
OSOlga Maria Duarte Silva
Olga Maria Duarte Silva
Species of the Diospyros L. genus (Ebenaceae family) have been largely used in traditional medicine for the treatment of several diseases, especially infectious ones. To date, active major compounds such as naphthoquinones, triterpenoids, and tannins have been isolated and pharmacologically validated from Diospyros species. The present study summarizes the information available in the literature on the species described in the Flora of Mozambique. To do so, scientific databases (e.g., PubMed, Scopus, Web of Science, and Google Scholar) were searched using various keywords and Boolean connectors to gather and summarize the information. Of the 31 native and naturalized species in the Flora of Mozambique, 17 are used in different regions of Africa and were described for their traditional uses. They were reported to treat more than 20 diseases, mostly infectious, in the gastrointestinal and oral cavity compartments. This work provides an overview of the therapeutical potential of Diospyros species and explores novel insights on the antimicrobial potential of extracts and/or isolated compounds of these Mozambican species.

3 December 2024 in Bacteria
Verified
Journal Article
Open access
PDF file
RARahaf Alsayyed
Rahaf Alsayyed
Adriana RibeiroAdriana Ribeiro
Adriana Ribeiro
HCHelena Cabral-Marques
Helena Cabral-Marques
Antibiotic-resistance (ABR) poses a critical public health challenge within the broader antimicrobial resistance crisis. This review evaluates the potential of polyelectrolytes (PEs) and polyelectrolyte complexes (PECs) for controlled antibiotic delivery as a strategy to combat ABR and biofilm-related infections. PECs, particularly those incorporating chitosan and other polycations, enhance antibacterial efficacy by disrupting bacterial cell walls and obstructing their nutrient flow. They are also effective in penetrating biofilms and providing sustained drug release. Despite these advantages, there is a need for further in vivo research and clinical trials to validate these findings. This review provides a comprehensive overview of PECs’ potential to advance antibacterial therapies and outlines future research directions to further explore their applications.

9 September 2024 in Future Pharmacology
Verified
Journal Article
Open access
PDF file
Adriana RibeiroAdriana Ribeiro
Adriana Ribeiro
RARahaf Alsayyed
Rahaf Alsayyed
DODaniele Oliveira
Daniele Oliveira
RLRui Loureiro
Rui Loureiro
HCHelena Cabral-Marques
Helena Cabral-Marques
Cannabis sativa L. has garnered attention as a potential source for new antimicrobial agents, particularly due to the increased prevalence of microbial resistance to conventional antimicrobials and the emergence of multidrug-resistant pathogens. This review, conducted according to the PRISMA 2020 statement, systematically analyzed the antimicrobial properties of C. sativa extracts and cannabinoids against various bacteria, fungi, viruses, and parasites. Data were collected from the scientific literature (102 papers) and clinical trials (5 studies) from 2014 to June 2024. Findings revealed that cannabinoids, especially CBD, demonstrate significant antimicrobial activity against Gram-positive bacteria like MRSA, Gram-negative bacteria such as Pseudomonas aeruginosa, various Candida species, SARS-CoV-2, and HIV. Additionally, CBD showed efficacy against parasitic infections like Echinococcus granulosus and Leishmania species. These results suggest that cannabinoids may represent a new class of antimicrobial agents with unique and diverse mechanisms of action, potentially effective in broad-spectrum therapies. This study highlights the urgent need for further research and standardized clinical trials to validate these findings and to develop cannabinoid-based treatments. The antimicrobial properties of C. sativa align with WHO priorities and support global health initiatives, offering promising avenues for addressing antimicrobial resistance and improving public health outcomes.
1

13 November 2024 in Molecules
Verified
Journal Article
Open access
PDF file
Adriana RibeiroAdriana Ribeiro
Adriana Ribeiro
RLRui Loureiro
Rui Loureiro
HCHelena Cabral-Marques
Helena Cabral-Marques
Chronic pain (CP), including pain related to cancer, affects approximately 2 billion people worldwide, significantly diminishing quality of life and imposing socio-economic burdens. Current treatments often provide limited relief and may cause adverse effects, demanding more effective alternatives. Natural compounds from Cannabis sativa L., particularly cannabinoids like THC and CBD, exhibit analgesic and anti-inflammatory properties, but their therapeutic use is restricted by poor solubility and low bioavailability. Cyclodextrins (CDs) and cyclic oligosaccharides may encapsulate hydrophobic drugs in order to enhance their solubility and stability, offering a promising solution to these challenges. This study explores the formation of CD inclusion complexes with cannabinoids and specific terpenes, such as D-limonene (LIM), beta-caryophyllene (BCP), and gamma-terpinene (γ-TPN), aiming to improve pharmacokinetic profiles and therapeutic efficacy. We discuss analytical techniques for characterizing these complexes and their mechanisms of action, highlighting the potential of CDs to optimize drug formulations. The integration of CDs in cannabinoid therapies may enhance patient compliance and treatment outcomes in CP management. Future research should focus on innovative formulations and delivery systems to maximize the clinical applications of those compounds.

14 December 2022 in Plants
Verified
Journal Article
Open access
PDF file
Adriana RibeiroAdriana Ribeiro
Adriana Ribeiro
RSRita Serrano
Rita Serrano
ISIsabel Bettencourt Moreira da Silva
Isabel Bettencourt Moreira da Silva
EGElsa T. Gomes
Elsa T. Gomes
JPJoão F. Pinto
João F. Pinto
OSOlga Maria Duarte Silva
Olga Maria Duarte Silva
Diospyros villosa L. (De Winter) (Ebenaceae) is a shrub whose root (DVR) is used as a toothbrush and to treat oral infections in Mozambique. The present work aims at establishing monographic quality criteria to allow the sustainable and safe development of pharmaceutical preparations with this herbal drug. This includes setting botanical (qualitative and quantitative) and chemical identification parameters, purity tests (loss on drying and total ash), quantifying the major classes of constituents identified, and particle size characterization of the powdered drug. DVR samples are cylindrical and microscopically characterized by: a periderm, with six layers of flattened phellem cells, with slightly thickened walls and few layers of phelloderm; cortical parenchyma with brachysclereids with a short, roughly isodiametric form (13.82–442.14 μm2 × 103), surrounded by a ring of prismatic calcium oxalate crystals; uniseriate medullary rays and prominent vessels of the xylem with single or double shape; numerous single and clustered starch grains, within the cortical parenchyma, medullar parenchyma, and ray cells. Polyphenols, mainly hydrolyzable tannins (212.29 ± 0.005 mg gallic acid equivalent/g of dried DVR), are the main marker class of constituents. Furthermore, the average diameter of the particles of the powder, 0.255 mm, allows its classification as a fine powder.